FDA Diabetes Panel Fattens Lineup With April 1 Review Of Onglyza
This article was originally published in The Pink Sheet Daily
Executive Summary
Bristol-Myers stays mum on cardiovascular events in trials; agency’s demands are soon to become clearer.
You may also be interested in...
Bristol/AZ Saxagliptin Safety Review: All Signs Point to Positive Committee Outcome
Upcoming FDA advisory committee review of DPP4 inhibitor poses first test of new diabetes cardiovascular safety guidelines. Bristol and AstraZeneca won’t be the only companies watching carefully.
Bristol/AZ Saxagliptin Safety Review: All Signs Point to Positive Committee Outcome
Upcoming FDA advisory committee review of DPP4 inhibitor poses first test of new diabetes cardiovascular safety guidelines. Bristol and AstraZeneca won’t be the only companies watching carefully.
Novo Nordisk Makes Case For Alogliptin-Shadowed Victoza
Novo hopes the differing drug class and bigger Phase III trial will help diabetes drug get past heart-safety rules that tripped up the compound from Takeda.